ORIC reports Q2 2022 cash $237.8M; three Phase 1 readouts expected 1H 2023

Oric Pharmaceuticals, Inc.

2022-Q2 EPS reported -$1.10

Cash and investments $237.8M as of June 30, 2022; funds operations into 2H 2024.
R&D expenses $13.8M for Q2 2022, down from $15.5M in Q2 2021, mainly on lower ORIC-101 costs.
G&A expenses $6.9M for Q2 2022, up from $5.5M in Q2 2021, due to higher personnel costs.
Three ongoing Phase 1 programs (ORIC-533, ORIC-114, ORIC-944) with initial data expected 1H 2023.
Preclinical data on PLK4 inhibitor program presented at AACR in April 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.